Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial

This prospective multicentre phase II study characterises the toxicity and activity of first-line capecitabine and oxaliplatin combination therapy (CAPOX) in advanced biliary system adenocarcinomas. Patients received oxaliplatin (130 mg m(−2), day 1) plus capecitabine (1000 mg m(−2) b.i.d., days 1–1...

Descripción completa

Detalles Bibliográficos
Autores principales: Nehls, O, Oettle, H, Hartmann, J T, Hofheinz, R-D, Hass, H G, Horger, M S, Koppenhöfer, U, Hochhaus, A, Stieler, J, Trojan, J, Gregor, M, Klump, B
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361467/
https://www.ncbi.nlm.nih.gov/pubmed/18182984
http://dx.doi.org/10.1038/sj.bjc.6604178

Ejemplares similares

Ejemplares similares